Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

CV Sciences Reports Narrowed Q3 2026 Net Loss of $0.09 Million on $3.03 Million Revenue

CV Sciences experienced a revenue contraction to $3.03 million during the third quarter of 2026, yet successfully narrowed its net loss to $0.09 million. The financial performance was aided by a significant legal settlement gain and positive operational cash flow despite broader year-to-date headwinds.

Grocery store, supermarket, retail, aisle. Stock photo illustrating CV Sciences' financial results story.
CV Sciences, Inc. · Photo: ccipeggy / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 3.033.26
Gross Profit 1.511.58
Pretax Income -0.09-0.38
Net Income -0.09-0.38
Diluted EPS -0.00-0.00
Net Income YoY
+75.7%

Key highlights

  • Revenue declined to $3.03 million from $3.26 million in the prior year period
  • Net loss narrowed significantly by 75.7% year-over-year to $0.09 million
  • Company recorded a $0.5 million gain resulting from a legal settlement
  • Generated positive cash flow from operations of $0.18 million during the quarter
  • Nine-month net loss widened to $1.5 million compared to $0.8 million in 2025

How the Period Went

CV Sciences reported a revenue decrease for the third quarter of 2026, with top-line figures reaching $3.03 million compared to $3.26 million in the same period last year. This decline reflects ongoing challenges in product sales volumes within the competitive wellness market. However, the company demonstrated a notable reduction in its bottom-line deficit. The net loss for the quarter narrowed to $0.09 million, representing a 75.7% improvement over the $0.38 million net loss reported in the third quarter of 2025. This move toward break-even was primarily influenced by non-operating gains rather than core organic sales growth.

Margins and Profitability

Gross profit for the quarter stood at $1.51 million, down from $1.58 million in the prior year, essentially tracking the overall revenue decline. Despite the lower gross intake, the company's profitability profile was bolstered by a $0.5 million gain recognized from a legal settlement. This one-time item was critical in offsetting operational expenses during the three-month period. Furthermore, CV Sciences achieved a positive milestone in liquidity by generating $0.18 million in cash flow from operations. This quarterly cash generation contrasts with the wider $1.5 million net loss recorded over the full nine-month period ending September 30, 2026, which was impacted by debt conversion losses.

Business Overview

CV Sciences, Inc. operates as a consumer wellness company specializing in hemp-derived cannabidiol products. The company is best known for its flagship brand, PlusCBD, which is distributed across various retail channels including health food stores and e-commerce platforms. Its product portfolio encompasses a range of delivery formats such as oils, capsules, gummies, and topicals. The business focuses on the high-quality, science-backed segment of the hemp industry, targeting consumers seeking alternative wellness solutions for stress, sleep, and pain management. The company maintains a dual focus on its consumer product division and the development of plant-based prescription drug candidates.

Industry Landscape

The hemp-derived CBD industry continues to face a complex landscape characterized by intense competition and a lack of clear federal regulatory frameworks in the United States. Many peers in the cannabinoid space have reported similar revenue pressures as the market remains oversaturated with brands vying for limited retail shelf space. Changes in consumer spending habits and the rise of alternative hemp-derived cannabinoids have further fragmented demand. Companies in this sector are increasingly focusing on cost containment and operational efficiency to navigate these headwinds while waiting for potential legislative clarity regarding the regulation of CBD as a dietary supplement.

Source verified

SEC filing by CV Sciences, Inc. announcing financial results for the quarter ended September 30, 2026.

Read the filing ↗

Track CV Sciences, Inc. live

Get the next CV Sciences, Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.